BioSpace News Archive

Medline has entered into a multi-year prime vendor laboratory partnership with Allina Health. As the primary supplier, Medline will provide an extensive portfolio of laboratory products and solutions to Allina Health’s 15 laboratories across the system’s medical centers, hospitals, physician offices and urgent care facilities.

Waters Corporation introduced new, innovative powder rheology tooling and software for its TA Instruments™ HR Rheometers allowing scientists to make preciseii, repeatable powder rheology measurements simpler and faster.

Imvax, Inc., a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies, is presenting data today at the 2022 International Cancer Immunotherapy Conference (CICON) in New York City, NY.

Haleon plc announced the commencement of offers to exchange seven series of outstanding unregistered notes issued by GSK Consumer Healthcare Capital US LLC and GSK Consumer Healthcare Capital UK plc, as previously disclosed in Haleon’s public filings and pursuant to a registration rights agreement entered into at the time of the original issuance of the notes.

MaaT Pharma (EURONEXT: MAAT – the “Company”), a French clinical-stage biotech and a pioneer in the development of Microbiome Ecosystem Therapies™ (MET) dedicated to improving survival outcomes for patients with cancer, today announced its half year financial results for the six-month period ended June 30, 2022 and provided a business overview.

Latest Study on “Adrenocorticotropic Hormone [ACTH] Market Size, Share, Trends, Growth, Production, Consumption, Revenue, Company Analysis and Forecast 2022-2030”.

Latest Study on “CAR T-Cell Therapy Market Size, Share, Trends, Growth, Production, Consumption, Revenue, Company Analysis and Forecast 2022-2030”.

TearClear, an ophthalmic pharmaceutical company that transforms trusted drugs into branded best-in-class therapies, announced today that the company’s lead product, TC-002 (latanoprost ophthalmic solution 0.005%) met the primary and all secondary endpoints in the CLEAR Phase 3 pivotal trial.

Illumina, Inc. announced the launch of the NovaSeq™ X Series, new production-scale sequencers that will push the limits of what is possible with genomic medicine, enabling faster, more powerful, and more sustainable sequencing.

According to Nova one advisor, the global Retinal Vein Occlusion market was valued at USD 18.2 billion in 2021 and it is expected to hit around USD 34.7 billion by 2030 with a CAGR of 8.4% during the forecast period 2022 to 2030.